Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Stock Information for SRAX Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SRAX Inc

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 - A Potent Inhibitor of Cancer Metabolism
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
Lantern Pharma Receives Regulatory Approval to Expand Harmonic(TM) Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.